Disc Medicine Shares Rise 31.5% on Day of Positive Phase 3 Results
Photo: TokenPost
Disc Medicine, Inc. (IRON) announced positive results Monday from its Phase 3 APOLLO trial, and a separate morning snapshot that day placed its shares 31.5% above Friday’s close. The trial tested bitopertin in patients with erythropoietic protoporphyria and X-linked protoporphyria, conditions that cause painful reactions to light. At 10:00:16 a.m. ET (14:00:16 UTC) on Oct. 19, shares were quoted at $74.74, compared with a $56.84 close Friday, Oct. 16. The Monday reading was taken before the session ended, so it was not a closing price. Friday’s finish was up 19 cents, or 0.34%, from the previous session’s $56.65 close.
Source: TokenPost
